26.75
-0.05 (-0.19%)
| Previous Close | 26.80 |
| Open | 26.85 |
| Volume | 6,256,720 |
| Avg. Volume (3M) | 7,242,348 |
| Market Cap | 19,145,005,056 |
| Price / Sales | 1.39 |
| Price / Book | 4.49 |
| 52 Weeks Range | |
| Earnings Date | 6 Feb 2026 |
| Operating Margin (TTM) | -4,823.84% |
| Diluted EPS (TTM) | -0.750 |
| Quarterly Revenue Growth (YOY) | -16.10% |
| Quarterly Earnings Growth (YOY) | -96.70% |
| Total Debt/Equity (MRQ) | 1.93% |
| Current Ratio (MRQ) | 33.47 |
| Operating Cash Flow (TTM) | -839.45 M |
| Levered Free Cash Flow (TTM) | -375.20 M |
| Return on Assets (TTM) | -10.73% |
| Return on Equity (TTM) | -12.54% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Roivant Sciences Ltd. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 4.0 |
| Average | 1.63 |
|
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 30.31% |
| % Held by Institutions | 83.49% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Sb Investment Advisers (Uk) Ltd | 30 Sep 2025 | 40,315,127 |
| Qvt Financial Lp | 30 Sep 2025 | 29,381,635 |
| Viking Global Investors Lp | 30 Sep 2025 | 23,594,831 |
| Patient Square Capital Lp | 30 Sep 2025 | 12,480,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 35.00 (Citigroup, 30.84%) | Buy |
| Median | 33.00 (23.36%) | |
| Low | 30.00 (Guggenheim, 12.15%) | Buy |
| Average | 32.60 (21.87%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 25.23 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citigroup | 10 Feb 2026 | 35.00 (30.84%) | Buy | 27.35 |
| HC Wainwright & Co. | 10 Feb 2026 | 33.00 (23.36%) | Buy | 27.35 |
| 12 Dec 2025 | 26.00 (-2.80%) | Buy | 22.10 | |
| Guggenheim | 09 Feb 2026 | 30.00 (12.15%) | Buy | 27.67 |
| Goldman Sachs | 15 Dec 2025 | 33.00 (23.36%) | Buy | 21.90 |
| Leerink Partners | 15 Dec 2025 | 32.00 (19.63%) | Buy | 21.90 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |